Estrogen and dementia: Insights from the Women's Health Initiative Memory Study

JAMA

Volumn 291, Issue 24, 2004, Pages 3005-3007

  Schneider, Lon S ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; CONJUGATED ESTROGEN; MEDROXYPROGESTERONE ACETATE;

ALZHEIMER DISEASE; DEMENTIA; EDITORIAL; FOLLOW UP; HORMONAL THERAPY; PRIORITY JOURNAL; SCREENING TEST; SEX DIFFERENCE; AGED; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; ESTROGEN THERAPY; FEMALE; HUMAN; NOTE; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; RISK;

AGED; COGNITION DISORDERS; DEMENTIA; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); FEMALE; HUMANS; MEDROXYPROGESTERONE 17-ACETATE; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIALS; RISK;

EID: 2942748271     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.291.24.3005     Document Type: Editorial

References (24)

1. Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health. 1998;88:1337-1342.
2. Henderson VW, Paganini-Hill A, Emanuel CK, et al. Estrogen replacement therapy in older women: comparison between Alzheimer's disease cases and nondemented control groups. Arch Neurol. 1994;51:896-900.
3. Waring SC, Rocca WA, Petersen RC, et al. Postmenopausal estrogen replacement therapy and risk of AD: a population-based study. Neurology. 1999;52:965-970.
4. Kawas C, Resnick SM, Morrison A, et al. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer disease: the Baltimore Longitudinal Study on Aging. Neurology. 1997;48:1517-1521.
5. Tang MX, Jacobs D, Stern Y, et al. Effect of estrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet. 1996;348:429-432.
6. Yaffe K, Sawaya G, Lieberburg I, Grady D. Estrogen therapy in postmenopausal women: effects on cognitive function and dementia. JAMA. 1998;279:688-695.
7. Zandi PP, Carlson MC, Plassman BL, et al. Hormone replacement therapy and the incidence of Alzheimer disease in older women: the Cache County Study. JAMA. 2002;288:2123-2129.
8. Schneider LS, Finch C. Can estrogen prevent neurodegeneration? Drugs Aging. 1997;11:87-95.
9. Turgeon JL, McDonnell DP, Martin KA, Wise PM. Hormone therapy: physiological complexity belies therapeutic simplicity. Science. 2004;304:1269-1273.
10. Shumaker SA, Legault C, Kuller L, et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA. 2004;291:2947-2958.
11. Espeland MA, Rapp SR, Shumaker SA, et al. Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study. JAMA. 2004;291:2959-2968.
12. Shumaker SA, Legault C, Rapp SR. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA. 2003;289:2651-2662.
13. Rapp SR, Espeland MA, Shumaker SA, et al. Effect of estrogen plus progestin on global cognitive function in postmenopausal women: Women's Health Initiative Memory Study: a randomized controlled trial. JAMA. 2003;289:2663-2672.
14. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-333.
15. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004;291:1701-1712.
16. Shumaker SA, Reboussin BA, Espeland MA, et al. The Women's Health Initiative Memory Study (WHIMS): a trial of the effect of estrogen therapy in preventing and slowing the progression of dementia. Control Clin Trials. 1998;19:604-621.
17. Henderson VW, Paganini-Hill A, Miller BL, et al. Estrogen for Alzheimer's disease in women: randomized, double-blind, placebo-controlled trial. Neurology. 2000;54:295-301.
18. Mulnard RA, Cotman CW, Kawas C, et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease. JAMA. 2000;283:1007-1015.
19. Wang PN, Liao SQ, Liu RS, et al. Effects of estrogen on cognition, mood, and cerebral blood flow in AD: a controlled study. Neurology. 2000;54:2061-2066.
20. Hogervorst E, Yaffe K, Richards M, Huppert F. Hormone replacement therapy for cognitive function in postmenopausal women. Cochrane Database Syst Rev [serial online]. 2002:CD003122.
21. Holmes C, Cairns N, Lantos P, et al. Validity of current clinical critera for Alzheimer's disease, vascular dementia, and dementia with Lewy bodies. Br J Psychiatry. 1999;174:45-60.
22. Lim A, Tsuang D, Kukull, et al. Clinico-neuropathological correlation of Alzheimer's disease in community-based series. J Am Geriatr Soc. 1999;47:564-569.
23. Snowdon DA, Greiner LH, Mortimer JA, et al. Brain infarction and the clinical expression of Alzheimer disease: the Nun Study. JAMA. 1997;277:813-817.
24. Resnick SM, Henderson VW. Hormone therapy and risk of Alzheimer disease: a critical time. JAMA. 2002;288:2170-2172.